Stock 002099 ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Hisoar Pharmaceutical Co., Ltd.

Equities

002099

CNE000001PY2

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
5.93 CNY -0.50% Intraday chart for Zhejiang Hisoar Pharmaceutical Co., Ltd. +7.62% -17.52%
Apr. 18 Hisoar Pharma's Unit Passes German Health Regulator's Inspection MT
Apr. 01 Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024. CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 9,373 7,317 11,525 13,759 13,338 11,347
Enterprise Value (EV) 1 7,690 5,811 10,169 12,220 12,094 10,858
P/E ratio 27.5 x 11.9 x 14.8 x 42.5 x 137 x 140 x
Yield 1.73% 6.38% 4.21% 0.24% 1.21% 0.71%
Capitalization / Revenue 4.06 x 2.69 x 3.92 x 5.57 x 5.37 x 4.2 x
EV / Revenue 3.33 x 2.14 x 3.46 x 4.94 x 4.87 x 4.02 x
EV / EBITDA 11.3 x 6.79 x 9.47 x 18 x 29.8 x 25.9 x
EV / FCF 18.6 x 15 x 16.5 x 16.9 x 30.1 x 152 x
FCF Yield 5.36% 6.69% 6.06% 5.92% 3.32% 0.66%
Price to Book 1.65 x 1.36 x 2.01 x 2.35 x 2.18 x 1.86 x
Nbr of stocks (in thousands) 1,621,610 1,618,820 1,618,715 1,618,715 1,618,715 1,618,715
Reference price 2 5.780 4.520 7.120 8.500 8.240 7.010
Announcement Date 4/3/18 2/17/19 1/22/20 4/28/21 4/22/22 4/24/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 2,309 2,719 2,941 2,471 2,485 2,704
EBITDA 1 681.6 855.5 1,074 678.6 406.2 420
EBIT 1 500.6 663.3 870.8 422.1 117.2 88.57
Operating Margin 21.68% 24.4% 29.6% 17.08% 4.72% 3.28%
Earnings before Tax (EBT) 1 399.9 697.3 912.5 393.5 123 100.8
Net income 1 342.2 605 770.8 319.7 95.23 88.01
Net margin 14.82% 22.25% 26.2% 12.94% 3.83% 3.25%
EPS 2 0.2100 0.3800 0.4800 0.2000 0.0600 0.0500
Free Cash Flow 1 412.5 388.7 616.7 723.9 401.5 71.41
FCF margin 17.87% 14.3% 20.97% 29.29% 16.16% 2.64%
FCF Conversion (EBITDA) 60.52% 45.43% 57.43% 106.68% 98.82% 17%
FCF Conversion (Net income) 120.55% 64.24% 80.01% 226.41% 421.58% 81.13%
Dividend per Share 2 0.1000 0.2883 0.3000 0.0200 0.1000 0.0500
Announcement Date 4/3/18 2/17/19 1/22/20 4/28/21 4/22/22 4/24/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 1,682 1,506 1,356 1,539 1,244 489
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 413 389 617 724 401 71.4
ROE (net income / shareholders' equity) 6.91% 11.5% 13.9% 5.52% 1.57% 1.41%
ROA (Net income/ Total Assets) 4.35% 5.72% 7.9% 3.79% 0.96% 0.67%
Assets 1 7,861 10,582 9,760 8,439 9,882 13,049
Book Value Per Share 2 3.500 3.330 3.540 3.620 3.780 3.770
Cash Flow per Share 2 2.030 1.210 0.9600 1.220 1.130 0.9200
Capex 1 149 256 161 74.2 230 179
Capex / Sales 6.45% 9.41% 5.46% 3% 9.24% 6.64%
Announcement Date 4/3/18 2/17/19 1/22/20 4/28/21 4/22/22 4/24/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. Stock Zhejiang Hisoar Pharmaceutical Co., Ltd.
-17.52% 1.32B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002099 Stock
  4. Financials Zhejiang Hisoar Pharmaceutical Co., Ltd.